Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc.
483
•Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc.•September 20, 2024

Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc. – FDA 483, Sep 20, 2024

Record Details

During an inspection conducted from September 16-20, 2024, the FDA issued a Form 483 to Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc., a drug product manufacturer. The inspection revealed significant deviations from current Good Manufacturing Practice (cGMP) regulations. Key violations included inadequate written procedures for cleaning and maintenance of manufacturing equipment, specifically fluid bed dryers, which lacked sufficient detail to ensure visual cleanliness and prevent cross-contamination. Furthermore, equipment and utensils were not adequately maintained, with observations of a discolored hose, a cracked film coating panel, and a gauge with condensate. The facility itself showed signs of disrepair, including an opening in a ceiling, a hole in a wall with stagnant water, and a rusted water bath in the Quality Control laboratory. The laboratory control system was also found deficient, with expired sample and reference standard preparations being stored and, in some cases, used for critical dissolution testing, compromising data integrity. Finally, the firm's quality system had inadequate complaint records and investigations, specifically for product complaints regarding the "lack of effect" for Trulance, where investigations failed to include essential steps like testing retain samples or reviewing stability data. UPM Pharmaceuticals is required to submit a comprehensive response detailing corrective and preventive actions to address these observations and ensure regulatory compliance.

Company
Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc.
Inspection date
September 20, 2024
Product type
drugs
Office
New Orleans District Office
People
  • Christopher Curtin (recipient)
  • Rodney L. Tinzie
  • William V. Millar (Self-employed)
View Company Profile

ID · 134d1f41-cf7a-4ebb-8fd9-058fb7ccef6a

Other documents for Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc.
  • EIR - 2019-04-12April 12, 2019
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.